Skip to content

A Six-Month Prospective Follow-Up Study of WB001

A Six-Month Prospective Follow-Up Study of WB001 in Mild to Moderate Postpartum Depression

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05693792
Enrollment
0
Registered
2023-01-23
Start date
2023-02-01
Completion date
2024-06-08
Last updated
2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Depression

Keywords

Postpartum Depression

Brief summary

This study is a 6-month follow-up study to WB001-001 conducted to assess and evaluate the durability of the effect of {WB001+TAU} beyond the 8-week treatment period.

Detailed description

This study is a 6-month prospective, observational follow-up study to the WB001-001 trial. Participants will be a convenience sample of those enrolled in the WB001-001 parent trial who consent to participate in a follow-up study at baseline for WB001-001. After completion of WB001-001's EOT assessment, those consenting to participate in the current study will be screened to confirm eligibility. Eligible participants will complete six assessment batteries (patient-reported outcomes \[PROs\]) on a monthly basis for a 6-month observation period.

Interventions

OTHERObservational

No treatment regimen will be deployed in this follow-up study.

Sponsors

Woebot Health
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
22 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

1. Must have prior enrollment in the WB001-001 trial and completion of Week 8/EOT 2. Must be willing and able to comply with all study procedures

Exclusion criteria

1\. Documented AE or SAE at WB001-001 Week 8 related to participant safety, by Investigator judgement

Design outcomes

Primary

MeasureTime frameDescription
Hamilton Rating Scale for Depression (HAM-D)Change from Baseline to Week 4; Change from Baseline to Week 8Clinician-rated measure of depression. The HAM-D6 is a subset of the HAM-D17 that assesses the 6 core items associated with major depression. Scores range from 0-22, where higher scores indicate greater depression severity.

Secondary

MeasureTime frameDescription
Edinburgh Postpartum Depression Scale (EPDS)Change from Baseline to Week 4; Change from Baseline to Week 8; Change from Baseline to Week 12; Change from Baseline to Week 16; Change from Baseline to Week 20; Change from Baseline to Week 24Measure of postpartum depression. A 10-item self-report questionnaire that assesses depression criteria and yields a total score from 0 to 30 where higher scores denote greater depression.
Generalized Anxiety Disorder Questionnaire (GAD-7)Change from Baseline to Week 4; Change from Baseline to Week 8; Change from Baseline to Week 12; Change from Baseline to Week 16; Change from Baseline to Week 20; Change from Baseline to Week 24Measure of anxiety. A 7-item brief self-report questionnaire, where total score range is between 0-21, with higher scores indicate greater levels of anxiety.
Patient Health Questionnaire (PHQ-9)Change from Baseline to Week 4; Change from Baseline to Week 8; Change from Baseline to Week 12; Change from Baseline to Week 16; Change from Baseline to Week 20; Change from Baseline to Week 24Measure of depression. A 9-item self-report questionnaire where total scores range from 0 to 27, with higher scores indicating greater levels of depression.
Patient Global Impression scale (PGI)Change from Baseline to Week 4; Change from Baseline to Week 8; Change from Baseline to Week 12; Change from Baseline to Week 16; Change from Baseline to Week 20; Change from Baseline to Week 24Measure of disease severity. A single-item scale asking respondents to rate the severity of their disease.
Columbia-Suicide Severity Rating Scale (C-SSRS)Change from Baseline to Week 4; Change from Baseline to Week 8; Change from Baseline to Week 12; Change from Baseline to Week 16; Change from Baseline to Week 20; Change from Baseline to Week 24Measure of risk for suicide. A clinician-administered assessment that measures four constructs: the severity of ideation, the intensity of ideation, behavior, and lethality. The C-SSRS consists of 10 categories with binary responses (Yes or No) to indicate the presence or absence of the behavior with a numerical score outcome.
Mother-to-Infant Bonding Scale (MIBS)Change from Baseline to Week 4; Change from Baseline to Week 8; Change from Baseline to Week 12; Change from Baseline to Week 16; Change from Baseline to Week 20; Change from Baseline to Week 24Measure of mother-infant bond. An 8-item self-report questionnaire, where total scores range from 0 to 24, with lower scores indicating good bonding.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026